Articles: nausea.
-
Expert Rev Anticancer Ther · Feb 2012
ReviewFosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
For patients receiving cancer chemotherapy, the ongoing development of antiemetic treatment is of significant importance. Patients consider nausea and vomiting among the most distressing symptoms of chemotherapy, and as new antiemetics have been very successful in prevention of vomiting, agents effective against nausea have become one of the major unmet needs. ⋯ Fosaprepitant (intravenous prodrug of aprepitant) given as a single intravenous dose of 150 mg can replace the aprepitant 3-day oral regimen. This article focuses on the development and clinical application of fosaprepitant.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jan 2012
Review Meta AnalysisProphylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
To systematically review the effectiveness and safety of 5-hydroxytryptamine-3 receptor antagonists (5-HT3 RAs) compared with other antiemetic medication or placebo for prophylaxis of radiation-induced nausea and vomiting. ⋯ 5-Hydroxytryptamine-3 RAs are superior to placebo and other antiemetics for prevention of emesis, but little benefit was identified for nausea prevention. 5-Hydroxytryptamine-3 RAs are suggested for prevention of emesis. Limited evidence was found regarding delayed emesis, adverse events, quality of life, or need for rescue medication. Future randomized, controlled trials should evaluate different 5-HT3 antiemetics and new agents with novel mechanisms of action such at the NK(1) receptor antagonists to determine the most effective drug. Delayed nausea and vomiting should be a focus of future study, perhaps concentrating on the palliative cancer population.
-
Nausea and vomiting are common gastrointestinal symptoms following opioid administration, for either chronic or acute pain management. As a consequence, patients' dissatisfaction has a negative impact on treatment efficacy. ⋯ Preventive strategies and therapeutic approaches are evaluated in the perioperative setting and in chronic pain. Newer drugs include second generation serotonin receptor antagonists (palonosetron) and neurokinin-1 (NK-1) antagonists (aprepitant).
-
J. Perianesth. Nurs. · Dec 2011
ReviewMeasurement of postdischarge nausea and vomiting for ambulatory surgery patients: a critical review and analysis.
Approximately one-third of patients experience nausea and vomiting after discharge from ambulatory surgery settings, yet there have been no clear and definitive instruments used to measure it. A critical review and analysis of the measurement of postdischarge nausea and vomiting was conducted. Twenty-eight articles met the inclusion criteria. ⋯ Definitions, measurement, and clinical outcomes were defined differently in each study. Of the instruments examined, the Ambulatory Surgery Inventory of Nausea, Vomiting, and Retching and Functional Living Index-Emesis provide the possibility for outcome standardization. Although both instruments possess strengths, more study is needed to advance the measurement of nausea and vomiting in the postdischarge ambulatory surgery patient.
-
J Pain Symptom Manage · Oct 2011
ReviewThe efficacy of acupressure for symptom management: a systematic review.
Acupressure is a noninvasive strategy used to manage various symptoms. ⋯ Acupressure may be a useful strategy for the management of multiple symptoms in a variety of patient populations, but rigorous trials are needed. Inclusion of acupressure as an intervention may improve patient outcomes.